Potential-dependent activities in interpreting the reaction mechanism of dual-metal atom catalysts for Li-CO2 batteries.

CO2 electrochemistry has been considered as a promising cathode reaction for energy storage due to its high theoretical energy density, high electrochemical potential, and ability to fix CO2. However, the low efficiency and poor reversibility of Li-CO2 evolution significantly impede the applications of Li-CO2 batteries. Herein, first-principles calculations were employed to investigate the 21 M1M2N4C dual-atom catalysts and explore the catalytic mechanism for the Li-CO2 evolution reaction. Among these dual-atom catalysts, the MoMoN4C shows the highest adsorption interaction with CO2 due to its high d-center and d-p orbital coupling. The effects of dual-atom sites on the catalytic activities and selectivities were investigated by searching the possible reaction pathways toward the battery-discharging processes in the ether electrolyte with the help of implicit constant electrode potential simulations. The compared results show that the Li-CO2 discharging process was limited by the rate-determining reactions involving *Li + CO2 → *LiCO2 and *LiC2O4@ + Li+ + e- → *CO + Li2CO3, and these processes on graphene are relatively sluggish due to the low onset potential range of -2 to -2.36 V vs. SHE. By contrast, The optimized onset potentials of -1.15 to -1.31 V vs. SHE were obtained at the MoMoN4C active site. Furthermore, the MoMoN4C active site shows a lower energy barrier for the decomposition of *Li2CO3 than the pure graphene, which reveals the MoMoN4C active site with excellent CO2 activation ability can reduce the polarization of the discharging reactions and energy barrier for the CO bond cleavage. This work provides deep insight into the Li-CO2 evolution mechanisms and guides the design of advanced dual-atom catalysts for highly reversible Li-CO2 batteries.

Comparison between the application of dyed medical glue and hookwires for the localization of pulmonary nodules.

Objectives: To compare the efficacy and safety of the localization of small pulmonary nodules (sPNs) with dyed medical glue (DMG) and hookwires prior to video-assisted thoracoscopic surgery (VATS). Materials and methods: A total of 344 patients were enrolled in this single-center retrospective cohort study between January 2018 and May 2022. There were 184 patients who underwent localization with DMG. From this amount, 160 patients underwent localization with hookwires. The localization success rate, localization-VATS interval time (LVIT), surgical resection time (SRT), and complications of the two groups were assessed. Results: VATS was successfully performed in all cases without conversion to thoracotomy. The localization success rate showed that the DMG group (100%, 184/184) had better results than the hookwire group (91.3%, 146/160) (P=0.004). The dyed glue group had a longer LVIT (P < 0.001) and shorter SRT (P=0.042). The rates of pulmonary hemorrhage (P < 0.001) and overall complications (P=0.009) in the DMG group were significantly lower than those in the hookwire group. An increased number of needle adjustments in the lung was associated with an increased incidence of pneumothorax (P=0.005), pulmonary hemorrhage (P=0.037), and overall complications (P=0.001). The prolonged time required for positioning was associated with an increased incidence of chest pain (P=0.002). Conclusions: Localization using DMG and hookwires is equally safe and effective for sPNs prior to resection with VATS. DMG localization was associated with fewer complications and resulted in a longer LVIT.

Highly Sensitive Immunochromatographic Detection of Zearalenone Based on Ultrabright Red-Emitted Aggregation-Induced Luminescence Nanoprobes.

Highly luminescent nanospheres have been demonstrated in enhancing the sensitivity of lateral flow immunoassay (LFIA) due to their loading numerous luminescent dyes. However, the photoluminescence intensities of existing luminescent nanospheres are limited due to the aggregation-caused quenching effect. Herein, highly luminescent aggregation-induced emission luminogens embedded nanospheres (AIENPs) with red emission were introduced as signal amplification probes of LFIA for quantitative detection of zearalenone (ZEN). Optical properties of red-emitted AIENPs were compared with time-resolved dye-embedded nanoparticles (TRNPs). Results showed that red-emitted AIENPs have stronger photoluminescence intensity on the nitrocellulose membrane and superior environmental tolerance. Additionally, we benchmarked the performance of AIENP-LFIA against TRNP-LFIA using the same set of antibodies, materials, and strip readers. Results showed that AIENP-LFIA exhibits good dynamic linearity with the ZEN concentration from 0.195 to 6.25 ng/mL, with half competitive inhibitory concentration (IC50) and detection of limit (LOD) at 0.78 and 0.11 ng/mL, respectively. The IC50 and LOD are 2.07- and 2.36-fold lower than those of TRNP-LFIA. Encouragingly, the precision, accuracy, specificity, practicality, and reliability of this AIENP-LFIA for ZEN quantitation were further characterized. The results verified that the AIENP-LFIA has good practicability for the rapid, sensitive, specific, and accurate quantitative detection of ZEN in corn samples.

Homogenization of electric field distribution facilitating the Zn anode reversibility.

The surface morphology of the zinc-metal electrode was modulated using different levels of physical polishing treatment. Modulating the surface scratches homogenized the deposition electric field and reduced the local current density. A reasonable surface treatment could limit the "tip effect" and bring homogeneous plating and stripping of the Zn electrode.

Quantum dot bead-based competitive immunochromatographic assay for enterotoxin aureus A detection in pasteurized milk.

Staphylococcal enterotoxin A (SEA) is an important biotoxin, produced by Staphylococcus aureus under appropriate conditions, and often contaminates milk and dairy products. Herein, an anti-SEA monoclonal antibody (anti-SEA mAb) was prepared by injecting the SEA protein in BALB/c mice, and a novel immunochromatographic assay (ICA) was developed for the rapid and sensitive determination of SEA in pasteurized milk by using highly luminescent quantum dot beads (QB) as signal amplification probe. Given the 1020-fold enhancement in the photoluminescence intensity of QB to the original quantum dot, the proposed QB-ICA exhibits high sensitivity for SEA determination in real milk samples with a limit of detection of 1.89 ng/mL, and shows good dynamic linearity for SEA quantitative detection from 2 to 150 ng/mL within 15 min of test time. The proposed QB-ICA also shows good selectivity to SEA detection with a negligible cross-reaction to common analogs, including staphylococcal enterotoxins B, C, D, and E. In addition, the accuracy and precision of QB-ICA were assessed by analyzing SEA-fortified milk samples. The average recoveries of intra- and interassays range from 85.5 to 128.1%, and the coefficients of variation range from 4.6 to 14.2%, indicating an acceptable accuracy for the quantitative detection of SEA in real milk samples. In summary, this work provides a powerful and rapid analysis tool for the sensitive monitoring of SEA contamination in pasteurized milk samples.

[CD11b agonist leukadherin-1 inhibits activation of TLR7 and TLR9 in mouse bone marrow-derived dendritic cells by blocking NF-κB p65 pathway].

Objective To study the effect of CD11b agonist leukadherin-1 (LA1) on Toll-like receptor 7 (TLR7)- and TLR9-induced activation of mouse bone marrow-derived dendritic cells (BMDCs) and its specific mechanism. Methods BMDCs were successfully induced and the concentrations of LA1 used in the study were determined by CCK-8 assay and annexin V-FITC/PI double staining. BMDCs were treated with LA1 for 2 hours followed by stimulation of TLR7 agonist R837 and TLR9 agonist CpG1826. The expression of BMDCs surface markers CD40, CD86 and MHC-II were detected by flow cytometry; IL-6, IL-12p40 and tumor necrosis factor α (TNF-α) in the cell culture supernatant were detected by ELISA; the phosphorylation of NF-κB p65 in BMDCs was detected by Western blotting. Results LA1 concentration below 20 µmol/L had no effect on the viability and apoptosis of BMDCs. LA1 pretreatment significantly inhibited R837- and CpG 1826-induced expression of CD40, CD86 and MHC-II , and the secretion of IL-6, IL-12p40 and TNF-α in BMDCs. Moreover, LA1 pretreatment significantly inhibited the phosphorylation of NF-κB p65 activated by R837 and CpG1826 in BMDCs. Conclusion CD11b agonist LA1 can significantly inhibit the activation of TLR7 and TLR9 in BMDCs by blocking the NF-κB p65 signaling pathway.

Parecoxib sodium pretreatment reduces myoclonus after etomidate: A prospective, double-blind, randomized clinical trial
.

OBJECTIVE: Myoclonus induced by etomidate during induction of general anesthesia is a common phenomenon. This prospective, randomized, saline-controlled clinical study was performed to evaluate the effect of parecoxib sodium pretreatment on the incidence and severity of etomidate-induced myoclonus. METHODS: 60 patients, American Society of Anesthesiologists (ASA) physical status I or II, aged 20 to 60 years, who were scheduled to undergo elective laparoscopic cholecystectomy under general anesthesia, were allocated randomly into one of two groups to receive parecoxib sodium 40 mg intravenous (group P, n = 30) or the same volume of saline (group S, n = 30) 30 minutes before administration of etomidate (0.3 mg/kg). Myoclonus was assessed on a scale of 0 - 3. Postoperative side effects were recorded. RESULTS: The two groups were comparable with regard to baseline characteristics. The incidence of myoclonus was significantly lower in the parecoxib sodium group (11/30; 37%) than in the saline group (21/30; 70%) (p < 0.05). The severity of myoclonic movements was also significantly reduced by parecoxib sodium (p < 0.05). There were no significant differences between the two groups with respect to postoperative side effects. CONCLUSIONS: Pretreatment with intravenous injection of parecoxib sodium 40 mg significantly reduced the incidence and severity of etomidate-induced myoclonus without significant side effects.
.

A meta-analysis of the benefits of mindfulness-based stress reduction (MBSR) on psychological function among breast cancer (BC) survivors.

BACKGROUND: Psychological issue is the most common co-morbidity of women with breast cancer (BC) after receiving treatment. Effective coping with this problem is significant importance. The aim of this meta-analysis is to evaluate the benefits of mindfulness-based stress reduction (MBSR) on psychological distress among breast cancer survivors. METHODS: PUBMED, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched from their inception to June 30, 2014. Two reviewers independently reviewed and extracted the data. The primary outcomes of interest were psychological domains. Review Manager 5.3 was used to pool collected data. RESULTS: Nine articles involving 964 participants were identified. Compared with those in control group, patients in MBSR group have a significant improvement on psychological domains: depression [mean difference (MD), 5.09; 95 % confidence interval (CI), 3.63-6.55; P < 0.00001], anxiety (MD, 2.79; 95 % CI, 1.62-3.96; P < 0.00001), stress (MD, 4.10; 95 % CI, 2.46-5.74; P < 0.00001). MBSR can also improve the overall quality of life (QOL) (MD, -1.16; 95 % CI, -2.21 to -0.12; P = 0.03). CONCLUSIONS: On the basis of our findings, MBSR shows a positive effect on psychological function and QOL of breast cancer survivors. This approach can be recommended to breast cancer patients as a part of their rehabilitation.

Parecoxib sodium reduces the need for opioids after tonsillectomy in children: a double-blind placebo-controlled randomized clinical trial.

OBJECTIVE: Postoperative pain is a common phenomenon after pediatric tonsillectomy. This prospective randomized double-blind placebo-controlled clinical trial was performed to evaluate the analgesic efficacy of intravenous parecoxib sodium in children undergoing tonsillectomy. METHODS: Sixty children (American Society of Anesthesiologists physical status I-III, aged three to seven years, and scheduled to undergo elective tonsillectomy under general anesthesia) were randomly allocated into one of two groups to receive intravenous parecoxib sodium 1 mg·kg(-1) (Group P, n = 30) or the same volume of saline (Group S, n = 30) just after induction of general anesthesia. Between-group comparisons were made for the number of patients requiring rescue morphine, total number of doses of postoperative rescue morphine, time to first rescue analgesic, postoperative pain and sedation scores, and adverse effects. RESULTS: Rescue morphine was given to more children in Group S (25/30, 83%) than in Group P (17/30, 57%) [relative risk (RR), 1.5; 95% confidence interval (CI), 1.0 to 2.1; P = 0.024]. The mean (SD) time to first rescue analgesic was shorter in Group S than in Group P [132 (54) min vs 193 (78) min, respectively; mean difference, 61; 95% CI, 26.6 to 96.1; P = 0.001]. The median (interquartile range [IQR]) Children's Hospital of Eastern Ontario Pain Scale scores in the postanesthesia care unit were lower in Group P than in Group S (7 [5-8] vs 9 [8-11], respectively; P = 0.001). The incidence of postoperative nausea and vomiting (PONV) was higher in Group S than in Group P [11/30 (37%) vs 4/30 (13%), respectively; RR, 2.8; 95% CI, 1.0 to 7.7; P = 0.037]. CONCLUSIONS: A single intravenous injection of parecoxib sodium 1 mg·kg(-1) after anesthesia induction is an effective method for the control of postoperative pain. It provides a morphine-sparing effect, prolongs the time to first rescue analgesic, and reduces PONV in children undergoing tonsillectomy.

Effect of parecoxib sodium on postoperative shivering: a randomised, double-blind clinical trial.

BACKGROUND: Postoperative shivering is one of the most common complications in patients recovering from general anaesthesia. Although a variety of pharmacological therapies have been used to control postoperative shivering, no ideal drug has been found to date. OBJECTIVES: The aim of this study was to compare the efficacy and accompanying side-effects of prophylactic parecoxib sodium with that of tramadol or placebo for the prevention of postoperative shivering. DESIGN: A randomised, double-blind clinical study. SETTING: Mianyang Central Hospital, Sichuan, China, from December 2011 to November 2012. PATIENTS: One hundred and twenty adult patients, ASA 1 or 2, aged 20 to 60 years and scheduled for elective abdominal surgery under general anaesthesia. Reasons for noninclusion included allergy to any of the medications used; severe cardiovascular disease; kidney or liver dysfunction; peptic ulcer; muscle disease; intraoperative blood or blood products transfusion; or a history of convulsions or fever. INTERVENTIONS: The patients were allocated randomly to receive parecoxib sodium 40 mg (Group P, n = 40), tramadol 2 mg kg (Group T, n = 40) or isotonic saline (Group S, n = 40) 30 min before the end of surgery. MAIN OUTCOME MEASURES: The primary outcome measure was the incidence of postoperative shivering. Secondary outcomes were scores for postoperative pain and sedation, and the incidence of postoperative nausea and vomiting. RESULTS: The incidence and severity of postoperative shivering were significantly lower in Groups P and T than in Group S (P < 0.001). The sedation scores were higher in Group T than in Groups P and S (P < 0.05). The incidence of postoperative nausea and vomiting was also significantly higher in Group T than in Groups P and S (P = 0.016). CONCLUSION: Intravenous injection of parecoxib sodium 40 mg before the end of surgery effectively reduces the occurrence and severity of postoperative shivering after general anaesthesia without significant side effects. TRIAL REGISTRATION: ChiCTR-TRC-12002870.